Human papillomavirus analysis as a prognostic marker following conization of the cervix uteri

被引:96
作者
Chua, KL [1 ]
Hjerpe, A [1 ]
机构
[1] HUDDINGE UNIV HOSP,KAROLINSKA INST,DEPT PATHOL F42,S-14186 HUDDINGE,SWEDEN
关键词
D O I
10.1006/gyno.1997.4753
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Cervical intraepithelial neoplasia grade 3 (GIN 3) is treated surgically. Follow-up of these patients is important to ensure successful treatment, The present study was undertaken to determine whether human papillomavirus (HPV) testing can be used to discriminate patients who will have recurrences from those who will not. It is composed of 26 patients who presented with recurrences of CIN and 22 patients who remained disease-free after treatment. DNA was extracted from paraffin-embedded cone biopsies of incident CIN 3, their corresponding follow-up Pap smears taken 3 months postoperatively, and their secondary cone biopsies of the recurrent lesions. The extracted DNA were then analyzed by PCR for the presence of HPV, The posttreatment cervical smears in the recurrent group had a (25/26) 96% HPV prevalence, while HPV DNA was not detectable in any of the 22 patients in the control group. The HPV types in both the initial and recurrent lesions correlated very well, This suggest that most recurrences are likely to be due to persisting lesions or subclinical HPV infections that had not been completely removed. Cytology alone was not sufficiently sensitive to discriminate the patients at risk for recurrences, It appears that HPV testing can be useful to monitor the therapeutic result. (C) 1997 Academic Press.
引用
收藏
页码:108 / 113
页数:6
相关论文
共 33 条
  • [1] BISTOLETTI P, 1988, CANCER-AM CANCER SOC, V62, P2056, DOI 10.1002/1097-0142(19881101)62:9<2056::AID-CNCR2820620931>3.0.CO
  • [2] 2-K
  • [3] Bollen LJM, 1996, CANCER-AM CANCER SOC, V77, P2538, DOI 10.1002/(SICI)1097-0142(19960615)77:12<2538::AID-CNCR17>3.0.CO
  • [4] 2-T
  • [5] PREVALENCE OF HUMAN PAPILLOMAVIRUS IN CERVICAL-CANCER - A WORLDWIDE PERSPECTIVE
    BOSCH, FX
    MANOS, MM
    MUNOZ, N
    SHERMAN, M
    JANSEN, AM
    PETO, J
    SCHIFFMAN, MH
    MORENO, V
    KURMAN, R
    SHAH, KV
    ALIHONOU, E
    BAYO, S
    MOKHTAR, HC
    CHICAREON, S
    DAUDT, A
    DELOSRIOS, E
    GHADIRIAN, P
    KITINYA, JN
    KOULIBALY, M
    NGELANGEL, C
    TINTORE, LMP
    RIOSDALENZ, JL
    SARJADI
    SCHNEIDER, A
    TAFUR, L
    TEYSSIE, AR
    ROLON, PA
    TORROELLA, M
    TAPIA, AV
    WABINGA, HR
    ZATONSKI, W
    SYLLA, B
    VIZCAINO, P
    MAGNIN, D
    KALDOR, J
    GREER, C
    WHEELER, C
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1995, 87 (11): : 796 - 802
  • [6] Chua KL, 1996, CANCER, V77, P121, DOI 10.1002/(SICI)1097-0142(19960101)77:1<121::AID-CNCR20>3.0.CO
  • [7] 2-6
  • [8] Chua KL, 1996, INT J CANCER, V68, P54, DOI 10.1002/(SICI)1097-0215(19960927)68:1<54::AID-IJC11>3.0.CO
  • [9] 2-6
  • [10] CHUA KL, 1995, ANAL QUANT CYTOL HIS, V7, P221